Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status

Journal of Cellular Biochemistry

Volumn 106, Issue 4, 2009, Pages 738-744

  Lv, Hezhe ^a   Fan, Ellen ^b   Sun, Suozhu ^c   Ma, Xiaoxiao ^a   Zhang, Xiaoyan ^a   Han, David M K ^b   Cong, Yu Sheng ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c General Hospital of the Second Artillery   (China)

Author keywords

BPH and prostate cancer; CCN family protein; Cyr61; p53

Indexed keywords

CYSTEINE RICH PROTEIN 61; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

CELL LINE, TUMOR; CYSTEINE-RICH PROTEIN 61; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 62649099176     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22075     Document Type: Article

References (36)

1. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. 1998. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34:275-382.
2. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 6:1215-1223.
3. Bok RA, Small EJ. 2002. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 12:918-926.
4. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang PC, Kuo ML. 2004. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96:364-375.
5. Chen CC, Lau LF. 2008. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol (in press).
6. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D. 2007. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE 2:e534.
7. Chen Y, Du XY. 2007. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 100:1337-1345.
8. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. 2003. Pathological and molecular aspects of prostate cancer. Lancet 361:955-964.
9. Downing SR, Jackson P, Russell PJ. 2001. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. A review of the evidence. Urol Oncol 6:103-110.
10. Feng P, Wang B, Ren EC. 2008. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol 40:98-109.
11. Han DK, Eng J, Zhou H, Aebersold R. 2001. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 19:946-951.
12. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. 1996. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 48:971-979.
13. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC, Jr., Brekken RA, Fleming JB. 2005. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 200:371-377.
14. Jay P, Bergé-Lefranc JL, Marsollier C, Méjean C, Taviaux C, Berta P. 1997. The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p. Oncogene 14:1753-1757.
15. Kwon S, Munroe X, Crawley SC, Lee HY, Spong S, Bradham D, Gum JR, Jr., Sleisenger MH, Kim YS. 2007. Expression of connective tissue growth factor in pancreatic cancer cell lines. Int J Oncol 31:693-703.
16. Lau LF, Lam SC. 1999. The CCN family of angiogenic regulators: The integrin connection. Exp Cell Res 248:44-57.
17. Leask A, Abraham DJ. 2006. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803-4810.
18. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, Chen WJ, Kuo ML. 2005. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/ cyclooxygenase-2 signaling pathway. Clin Cancer Res 11:5809-5820.
19. Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T, Oshimura M. 2005. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5:3205-3213.
20. Perbal B, Brigstock DR, Lau LF. 2003. Report on the second international workshop on the CCN family of genes. Mol Pathol 56:80-85.
21. Perbal B. 2004. CCN proteins: Multifunctional signalling regulators. Lancet 363:62-64.
22. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP. 1998. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 36:85-91.
23. Sakamoto S, Yokoyama M, Prakash K, Tsuruha JI, Masamoto S, Getzenberg RH, Kakehi Y. 2003. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. J Biomol Screen 8:701-711.
24. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y, Saito Y. 2004a. Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 61:305-317.
25. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, Kakehi Y. 2004b. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 145:2929-2940.
26. Sampath D, Winneker RC, Zhang Z. 2001. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: Regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 142:2540-2548.
27. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
28. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. 2000. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9:1133-1147.
29. Todorovicç V, Chen CC, Hay N, Lau LF. 2005. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol 171:559-568.
30. Tong X, O'Kelly J, Xie D, Mori A, Lemp N, McKenna R, Miller CW, Koeffler HP. 2004. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 23:4847-4855.
31. Tsai MS, Bogart DF, Castañeda JM, Li P, Lupu R. 2002. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21:8178-8185.
32. Unoki H, Furukawa K, Yonekura H, Ueda Y, Katsuda S, Mori M, Nakagawara K, Mabuchi H, Yamamoto H. 2003. Up-regulation of cyr61 in vascular smooth muscle cells of spontaneously hypertensive rats. Lab Invest 83:973-982.
33. Vlastimil S, Nicole G, Alexander D, Andreas M. 2006. Inhibition of centrosome protein assembly leads to p53-dependent exit from the cell cycle. J Cell Biol 174:625-630.
34. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J, Koeffler HP. 2001. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276:14187-14194.
35. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP. 2004a. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10:2072-2081.
36. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP. 2004b. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64:1987-1996.